Covid19 tanısı almış hastalarda Periostin, HIF1, Fosfolipaz A2 parametrelerinin serum düzeylerinin araştırılması
Project no. 23420 · Status: Kapanmış (Yayın bekleniyor) · 2021
Summary
<p>Sars-CoV-2 causes COVID-19 disease with a high mortality rate and symptoms such as acute respiratory failure. Once Sars-Cov-2 enters the cell and replicates, it stimulates proinflammatory cytokines for innate and adaptive immunity, viral replication, and clearance of infected cells. Excessive activation of macrophages and granulocytes causes a “Cytokine Storm” which results in tissue damage. Various cytokines are involved in stages of COVID-19 disease from mild to severe.</p><p>In this study, serum levels of inflammatory markers Periostin, HIF1a, and PLA2 were analyzed in blood samples taken on the first, 3rd and 7th days from 9 patients who came to the Emergency Department and were diagnosed with COVID-19 and approved to participate in the study. In addition, serum samples were taken from 30 healthy controls and the levels of these markers in healthy and patient serum were compared. Serum samples from patients and healthy controls were analyzed by ELISA method to measure the levels of biomarkers.</p><p>Considering the findings, there was a significant difference in Periostin levels between the samples taken on the first day of hospitalization and the 7th day of COVID-19 patients (p=0.016). With increasing inflammation, Periostin 7th day serum levels increased approximately 2 times compared to the first hospitalization day.</p><p>This study showed that Periostin is an important biomarker in COVID-19 disease and can be a potential source of information about the severity of the disease. This study is unique as it includes simultaneous analysis of serum Periostin, HIF1a, and PLA2 parameters in COVID-19 patients. The measurement of these parameters together has enabled us to obtain comprehensive data for the diagnosis and evaluation of COVID-19 disease and will have a place in terms of public health with the data that will shed light on the evaluation of the severity stage of the COVID-19 infection.</p>